Impact of Personalized Anemia Management on Quality of Life and Serum Albumin Levels in Maintenance Hemodialysis Patients.

AIMS/BACKGROUND: Anemia is a highly prevalent and clinically significant complication in maintenance hemodialysis (MHD) patients, markedly impairing quality of life and being associated with adverse prognosis. Conventional management strategies often lack sufficient individualization, potentially leading to suboptimal therapeutic outcomes. This study aimed to investigate the impact of personalized anemia management on quality of life and albumin levels in maintenance hemodialysis patients through a retrospective analysis. METHODS: A retrospective analysis was conducted involving 353 patients who received maintenance hemodialysis at the Affiliated Hospital of North Sichuan Medical College between March 2022 and March 2025. Based on the management approaches documented in their medical records, patients were divided into two groups: Those receiving routine medical care were assigned to the control group (n = 181), while those receiving personalized anemia management strategies were assigned to the observation group (n = 172). The observation group received personalized anemia management in addition to routine dialysis. Specifically, this approach included individualized adjustment of erythropoietin and iron dosages based on a comprehensive evaluation of dynamic hemoglobin and albumin levels, as well as nutritional status. Meanwhile, a multidisciplinary team led by physicians collaboratively formulated nutritional and pharmacological management plans and provided adherence guidance. The study compared changes in hemoglobin levels, hemoglobin target achievement rate, albumin levels, body composition parameters, Self-Rating Anxiety Scale (SAS), Self-Rating Depression Scale (SDS), quality of life scores (assessed using the Kidney Disease Quality of Life 36-Item Short Form Survey, KDQOL-36), and Pittsburgh Sleep Quality Index (PSQI) between the two groups before and after treatment. RESULTS: Following the intervention, depression and anxiety scores in the observation group were significantly lower than those in the control group (p < 0.05). Regarding physiological indicators, albumin levels, body composition parameters, hemoglobin levels, and the hemoglobin target achievement rate, the observation group showed significant improvements compared with the control group (p < 0.05). Additionally, the PSQI score was significantly lower in the observation group, whereas the quality of life scores were significantly higher compared with the control group; all differences were statistically significant (p < 0.05). CONCLUSION: Personalized anemia management significantly improves quality of life and albumin levels in maintenance hemodialysis patients and demonstrates potential for clinical application.